<VariationArchive VariationID="17611" VariationName="NM_001232.4(CASQ2):c.339_354del (p.Ser113fs)" VariationType="Deletion" Accession="VCV000017611" Version="11" RecordType="classified" NumberOfSubmissions="4" NumberOfSubmitters="4" DateLastUpdated="2024-07-29" DateCreated="2015-04-11" MostRecentSubmission="2024-02-14">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="32650" VariationID="17611">
      <GeneList>
        <Gene Symbol="CASQ2" FullName="calsequestrin 2" GeneID="845" HGNC_ID="HGNC:1513" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>1p13.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="115700021" stop="115768714" display_start="115700021" display_stop="115768714" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="116242623" stop="116311425" display_start="116242623" display_stop="116311425" Strand="-" />
          </Location>
          <OMIM>114251</OMIM>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_001232.4(CASQ2):c.339_354del (p.Ser113fs)</Name>
      <CanonicalSPDI>NC_000001.11:115740793:CTTAAGAATATACAGGCTT:CTT</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>1p13.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="115740794" stop="115740809" display_start="115740794" display_stop="115740809" variantLength="16" positionVCF="115740793" referenceAlleleVCF="CCTTAAGAATATACAGG" alternateAlleleVCF="C" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="116283415" stop="116283430" display_start="116283415" display_stop="116283430" variantLength="16" positionVCF="116283414" referenceAlleleVCF="CCTTAAGAATATACAGG" alternateAlleleVCF="C" />
      </Location>
      <ProteinChange>S113fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001232.3" sequenceAccession="NM_001232" sequenceVersion="3" change="c.339_354delCCTGTATATTCTTAAG">
            <Expression>NM_001232.3:c.339_354delCCTGTATATTCTTAAG</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000001.10" sequenceAccession="NC_000001" sequenceVersion="10" change="g.116283418_116283433del" Assembly="GRCh37">
            <Expression>NC_000001.10:g.116283418_116283433del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000001.11" sequenceAccession="NC_000001" sequenceVersion="11" change="g.115740797_115740812del" Assembly="GRCh38">
            <Expression>NC_000001.11:g.115740797_115740812del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008802.1" sequenceAccession="NG_008802" sequenceVersion="1" change="g.32997_33012del">
            <Expression>NG_008802.1:g.32997_33012del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001232.4" sequenceAccession="NM_001232" sequenceVersion="4" change="c.339_354del" MANESelect="true">
            <Expression>NM_001232.4:c.339_354del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001223.2" sequenceAccession="NP_001223" sequenceVersion="2" change="p.Ser113fs">
            <Expression>NP_001223.2:p.Ser113fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_404" sequenceAccession="LRG_404">
            <Expression>LRG_404:g.32997_33012del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001232.3" sequenceAccession="NM_001232" sequenceVersion="3" change="c.339_354del16">
            <Expression>NM_001232.3:c.339_354del16</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001232.3" sequenceAccession="NM_001232" sequenceVersion="3" change="c.339_354del">
            <Expression>NM_001232.3:c.339_354del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA258047" DB="ClinGen" />
        <XRef Type="Allelic variant" ID="114251.0002" DB="OMIM" />
        <XRef Type="rs" ID="786205106" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_001232.4(CASQ2):c.339_354del (p.Ser113fs) AND Catecholaminergic polymorphic ventricular tachycardia 2" Accession="RCV000019177" Version="37">
        <ClassifiedConditionList TraitSetID="6678">
          <ClassifiedCondition DB="MedGen" ID="C2677794">Catecholaminergic polymorphic ventricular tachycardia 2</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-04-11" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_001232.4(CASQ2):c.339_354del (p.Ser113fs) AND not provided" Accession="RCV000170902" Version="12">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-11-07" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_001232.4(CASQ2):c.339_354del (p.Ser113fs) AND Catecholaminergic polymorphic ventricular tachycardia 1" Accession="RCV002513117" Version="9">
        <ClassifiedConditionList TraitSetID="6589">
          <ClassifiedCondition DB="MedGen" ID="C1631597">Catecholaminergic polymorphic ventricular tachycardia 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2024-01-29" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-01-29" NumberOfSubmissions="4" NumberOfSubmitters="4" DateCreated="2015-04-11" MostRecentSubmission="2024-02-14">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">12386154</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">16908766</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="6678" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5103" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">VENTRICULAR TACHYCARDIA, STRESS-INDUCED POLYMORPHIC 2</ElementValue>
                <XRef Type="MIM" ID="611938" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Catecholaminergic polymorphic ventricular tachycardia 2</ElementValue>
                <XRef ID="MONDO:0012762" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">VTSIP2</ElementValue>
                <XRef Type="MIM" ID="611938" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">CPVT2</ElementValue>
                <XRef Type="MIM" ID="611938" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15535" />
                <XRef ID="15535" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Catecholaminergic polymorphic ventricular tachycardia (CPVT) is characterized by episodic syncope occurring during exercise or acute emotion. The underlying cause of these episodes is the onset of fast ventricular tachycardia (bidirectional or polymorphic). Spontaneous recovery may occur when these arrhythmias self-terminate. In other instances, ventricular tachycardia may degenerate into ventricular fibrillation and cause sudden death if cardiopulmonary resuscitation is not readily available. The mean onset of symptoms (usually a syncopal episode) is between age seven and 12 years; onset as late as the fourth decade of life has been reported. If untreated, CPVT is highly lethal, as approximately 30% of affected individuals experience at least one cardiac arrest and up to 80% have one or more syncopal spells. Sudden death may be the first manifestation of the disease.</Attribute>
                <XRef ID="NBK1289" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301466</ID>
                <ID Source="BookShelf">NBK1289</ID>
              </Citation>
              <Citation Type="general" Abbrev="HRS/EHRA, 2012">
                <ID Source="PubMed">21810866</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <XRef ID="3286" DB="Orphanet" />
              <XRef ID="C2677794" DB="MedGen" />
              <XRef ID="MONDO:0012762" DB="MONDO" />
              <XRef Type="MIM" ID="611938" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="6589" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="4488" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 1, WITH OR WITHOUT ATRIAL DYSFUNCTION AND/OR DILATED CARDIOMYOPATHY</ElementValue>
                <XRef Type="MIM" ID="604772" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Stress-induced polymorphic ventricular tachycardia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Catecholaminergic polymorphic ventricular tachycardia 1</ElementValue>
                <XRef ID="MONDO:0011484" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">VENTRICULAR TACHYCARDIA, STRESS-INDUCED POLYMORPHIC 1</ElementValue>
                <XRef Type="MIM" ID="604772" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">VTSIP1</ElementValue>
                <XRef Type="MIM" ID="604772" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">CPVT1</ElementValue>
                <XRef ID="GTR000520063" DB="Genetic Testing Registry (GTR)" />
                <XRef Type="MIM" ID="604772" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">VTSIP</ElementValue>
                <XRef Type="MIM" ID="604772" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Catecholaminergic polymorphic ventricular tachycardia (CPVT) is characterized by episodic syncope occurring during exercise or acute emotion. The underlying cause of these episodes is the onset of fast ventricular tachycardia (bidirectional or polymorphic). Spontaneous recovery may occur when these arrhythmias self-terminate. In other instances, ventricular tachycardia may degenerate into ventricular fibrillation and cause sudden death if cardiopulmonary resuscitation is not readily available. The mean onset of symptoms (usually a syncopal episode) is between age seven and 12 years; onset as late as the fourth decade of life has been reported. If untreated, CPVT is highly lethal, as approximately 30% of affected individuals experience at least one cardiac arrest and up to 80% have one or more syncopal spells. Sudden death may be the first manifestation of the disease.</Attribute>
                <XRef ID="NBK1289" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301466</ID>
                <ID Source="BookShelf">NBK1289</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="HRS/EHRA/APHRS, 2013">
                <ID Source="PubMed">23994779</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="general" Abbrev="HRS/EHRA, 2012">
                <ID Source="PubMed">21810866</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <XRef ID="3286" DB="Orphanet" />
              <XRef ID="C1631597" DB="MedGen" />
              <XRef ID="MONDO:0011484" DB="MONDO" />
              <XRef Type="MIM" ID="604772" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="39465" SubmissionDate="2015-04-08" DateLastUpdated="2015-04-11" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="114251.0002_VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 2" title="CASQ2, 16-BP DEL, NT339_VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 2" />
        <ClinVarAccession Accession="SCV000039465" DateUpdated="2015-04-11" DateCreated="2013-04-04" Type="SCV" Version="2" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2006-09-05">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In a 6-year-old boy with catecholaminergic polymorphic ventricular tachycardia (CPVT2; 611938), di Barletta et al. (2006) identified homozygosity for a 16-bp deletion (339del16) in exon 3 of the CASQ2 gene, predicted to generate a frameshift and result in a stop codon 5 amino acids downstream. Asymptomatic family members were found to be heterozygous carriers of the deletion; none of them developed ventricular arrhythmias during Holter or exercise stress test. Ca(2+) overlay experiments showed that CASQ2 containing the 16-bp deletion did not bind calcium. When expressed in rat myocytes, the 16-bp deletion-containing mutant decreased sarcoplasmic reticulum Ca(2+) storing capacity and reduced the amplitude of I(Ca)-induced Ca(2+) transients and of spontaneous Ca(2+) sparks in permeabilized myocytes, although the effects observed with the 16-bp deletion were much more prominent than those with L167H (114251.0003) mutant. Mutant myocytes with the 16-bp deletion exposed to isoproterenol developed delayed afterpolarizations.</Attribute>
              <Citation>
                <ID Source="PubMed">16908766</ID>
              </Citation>
              <XRef DB="OMIM" ID="611938" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CASQ2" />
          </GeneList>
          <Name>CASQ2, 16-BP DEL, NT339</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">16-BP DEL, NT339</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="114251.0002" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 2</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="406299" SubmissionDate="2023-11-22" DateLastUpdated="2023-11-25" DateCreated="2015-05-24">
        <ClinVarSubmissionID localKey="GDXSV:314441" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV000223459" DateUpdated="2023-11-25" DateCreated="2015-05-24" Type="SCV" Version="12" SubmitterName="GeneDx" OrgID="26957" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-11-07">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>Not observed at significant frequency in large population cohorts (gnomAD); Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Published functional studies in rat myocytes, showed the del16 mutation decreased the sarcoplasmic reticulum Ca2+ storing capacity and reduce the amplitude of calcium currents (PMID: 16908766); This variant is associated with the following publications: (PMID: 18469084, 16908766, 32693635)</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">GeneDx Variant Classification Process June 2021</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/fc81e176/genedx_variant_classification_process_june_2021.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CASQ2" />
          </GeneList>
          <VariantType>Deletion</VariantType>
          <OtherNameList>
            <Name Type="SubmitterVariantId">GDX:10544</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_001232.3:c.339_354del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not Provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GeneDX_Clinvar_Submission_236_20231122054204</SubmissionName>
          <SubmissionName>SUB5098196</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7575785" SubmissionDate="2023-10-18" DateLastUpdated="2023-10-28" DateCreated="2023-10-28">
        <ClinVarSubmissionID localKey="NM_001232.4:c.339_354del|OMIM:611938" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004048956" DateUpdated="2023-10-28" DateCreated="2023-10-28" Type="SCV" Version="1" SubmitterName="Genome-Nilou Lab" OrgID="507598" OrganizationCategory="laboratory" OrgAbbreviation="Genome Nilou" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-04-11">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>no</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CASQ2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_001232.4:c.339_354del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="611938" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13910671</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3105114" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2021-05-10">
        <ClinVarSubmissionID localKey="3325667|MedGen:C1631597" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001579509" DateUpdated="2024-02-14" DateCreated="2021-05-10" Type="SCV" Version="4" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-01-29">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">12386154</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">16908766</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Ser113Argfs*6) in the CASQ2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CASQ2 are known to be pathogenic (PMID: 12386154). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individuals with catecholaminergic polymorphic ventricular tachycardia (PMID: 16908766). This variant is also known as G112+5X. ClinVar contains an entry for this variant (Variation ID: 17611). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CASQ2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000001.10:g.116283415_116283430del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1631597" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12507860</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="39465" TraitType="Disease" MappingType="Name" MappingValue="VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 2" MappingRef="Preferred">
        <MedGen CUI="C2677794" Name="Catecholaminergic polymorphic ventricular tachycardia 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3105114" TraitType="Disease" MappingType="XRef" MappingValue="C1631597" MappingRef="MedGen">
        <MedGen CUI="C1631597" Name="Catecholaminergic polymorphic ventricular tachycardia 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="406299" TraitType="Disease" MappingType="Name" MappingValue="Not Provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7575785" TraitType="Disease" MappingType="XRef" MappingValue="611938" MappingRef="OMIM">
        <MedGen CUI="C2677794" Name="Catecholaminergic polymorphic ventricular tachycardia 2" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

